Trial Profile

Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic as Post-consolidation Therapy in Adult Patients With Acute Myeloid Leukemia

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acute myeloid leukaemia vaccine (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions; Pharmacodynamics
Sponsors GlaxoSmithKline; GSK

Most Recent Events

28 Jul 2016 Status changed from active, no longer recruiting to completed.
14 Aug 2015 Planned End Date changed from 1 Sep 2017 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
01 Feb 2013 Planned end date changed from 1 Oct 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com